Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belinostat in combination with carboplatin, paclitaxel, and bevacizumab for untreated NSCLC
NCT01090830Phase 2Terminated
- Sponsor
- Holy Cross Health
- Start
- Apr 2010
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of belinostat in non-small cell lung carcinoma (NSCLC), sponsored by Holy Cross Health. Started Apr 2010; status: terminated.
02
Drugs
belinostat
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT01090830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01090830.